Determination of β-Galactooligosaccharides (GOS) in Infant Formula and Adult Nutritionals: Single-Laboratory Validation, First Action 2021.01.


Journal

Journal of AOAC International
ISSN: 1944-7922
Titre abrégé: J AOAC Int
Pays: England
ID NLM: 9215446

Informations de publication

Date de publication:
04 Feb 2022
Historique:
received: 19 05 2021
revised: 30 06 2021
accepted: 02 07 2021
pubmed: 23 7 2021
medline: 11 2 2022
entrez: 22 7 2021
Statut: ppublish

Résumé

β-Galactooligosaccharides (GOS) are typically used in infant formula and adult nutritionals as a source of nondigestible oligosaccharides, which may bring beneficial effects through modulation of the gut microbiota. However, suitable methods for the determination of GOS in products with a high background of lactose do not exist. The aim of this work was to develop a method suitable for the determination of GOS in infant formula and adult nutritionals and demonstrate suitability through single laboratory validation. Reducing oligosaccharides are labeled with 2-aminobenzamide (2AB), separated by hydrophilic interaction LC, and determined assuming that all oligosaccharides give an equimolar response in the detector. The same sample is analyzed a second time after treatment with β-galactosidase to remove GOS. The difference in the determined oligosaccharides between the two measurements will be the GOS content of the sample. The method was validated in a single laboratory on infant formula and adult nutritionals. Recoveries were in the range 91.5-102%, relative standards of deviation (RSDr) were in the range 0.7-5.99%, and one sample had an RSDr of 8.30%. Except for the one sample with an RSDr of 8.30%, the performance is within the requirements outlined in the Standard Method Performance Requirements, which specifies recoveries in the range 90-110% and RSDr of below 6%. The method is suitable for the determination of GOS in infant formula and adult nutritionals. A method has been developed which is suitable for the determination of GOS in products with a high background concentration of lactose (infant fromula and adult nutritionals). The method does not require access to the GOS ingredient used for the production of the finished product. It is also possible to separately quantify the amount of GOS containing three or more monomeric units in order to support dietary fibre analysis.

Sections du résumé

BACKGROUND BACKGROUND
β-Galactooligosaccharides (GOS) are typically used in infant formula and adult nutritionals as a source of nondigestible oligosaccharides, which may bring beneficial effects through modulation of the gut microbiota. However, suitable methods for the determination of GOS in products with a high background of lactose do not exist.
OBJECTIVE OBJECTIVE
The aim of this work was to develop a method suitable for the determination of GOS in infant formula and adult nutritionals and demonstrate suitability through single laboratory validation.
METHODS METHODS
Reducing oligosaccharides are labeled with 2-aminobenzamide (2AB), separated by hydrophilic interaction LC, and determined assuming that all oligosaccharides give an equimolar response in the detector. The same sample is analyzed a second time after treatment with β-galactosidase to remove GOS. The difference in the determined oligosaccharides between the two measurements will be the GOS content of the sample. The method was validated in a single laboratory on infant formula and adult nutritionals.
RESULTS RESULTS
Recoveries were in the range 91.5-102%, relative standards of deviation (RSDr) were in the range 0.7-5.99%, and one sample had an RSDr of 8.30%. Except for the one sample with an RSDr of 8.30%, the performance is within the requirements outlined in the Standard Method Performance Requirements, which specifies recoveries in the range 90-110% and RSDr of below 6%.
CONCLUSIONS CONCLUSIONS
The method is suitable for the determination of GOS in infant formula and adult nutritionals.
HIGHLIGHTS CONCLUSIONS
A method has been developed which is suitable for the determination of GOS in products with a high background concentration of lactose (infant fromula and adult nutritionals). The method does not require access to the GOS ingredient used for the production of the finished product. It is also possible to separately quantify the amount of GOS containing three or more monomeric units in order to support dietary fibre analysis.

Identifiants

pubmed: 34293126
pii: 6325511
doi: 10.1093/jaoacint/qsab095
pmc: PMC8824811
doi:

Substances chimiques

Oligosaccharides 0
Lactose J2B2A4N98G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

142-158

Informations de copyright

© AOAC INTERNATIONAL 2021.

Références

Int J Anal Chem. 2014;2014:768406
pubmed: 24719617
Compr Rev Food Sci Food Saf. 2010 Sep;9(5):438-454
pubmed: 33467830
J AOAC Int. 2018 Jul 1;101(4):1270-1271
pubmed: 29986804
Acta Paediatr Suppl. 2005 Oct;94(449):14-7
pubmed: 16214759
Eur J Clin Nutr. 2020 Oct;74(10):1434-1441
pubmed: 31980746
J Agric Food Chem. 2011 Jun 22;59(12):6501-10
pubmed: 21553845
Anal Biochem. 1996 Sep 5;240(2):210-26
pubmed: 8811911
Pathogens. 2020 Oct 14;9(10):
pubmed: 33066613
Adv Nutr. 2013 Jan 01;4(1):8-15
pubmed: 23319118
J AOAC Int. 2002 Mar-Apr;85(2):417-23
pubmed: 11990028
J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):291-5
pubmed: 11964956
Int J Food Microbiol. 2010 Dec 15;144(2):285-92
pubmed: 21059476
Nutrition. 2007 Jan;23(1):1-8
pubmed: 17189085
J Appl Microbiol. 2013 Apr;114(4):1132-46
pubmed: 23240984
J Nutr. 1997 Mar;127(3):444-8
pubmed: 9082028
Chin Med J (Engl). 2004 Jun;117(6):927-31
pubmed: 15198901
Child Psychiatry Hum Dev. 2019 Feb;50(1):150-162
pubmed: 30030653
Food Chem. 2018 Oct 15;263:29-36
pubmed: 29784319
Am J Clin Nutr. 2008 Mar;87(3):785-91
pubmed: 18326619
Br J Nutr. 2013 Oct;110(7):1292-303
pubmed: 23507173
J Agric Food Chem. 2010 Mar 10;58(5):2787-94
pubmed: 20146472

Auteurs

Denis Cuany (D)

Société des Produits Nestlé S.A., Nestlé Research, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland.

Fikrey Andetsion (F)

Société des Produits Nestlé S.A., Nestlé Research, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland.

Xavier Fontannaz (X)

Société des Produits Nestlé S.A., Nestlé Research, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland.

Thierry Bénet (T)

Société des Produits Nestlé S.A., Nestlé Research, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland.

Véronique Spichtig (V)

Société des Produits Nestlé S.A., Nestlé Research, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland.

Sean Austin (S)

Société des Produits Nestlé S.A., Nestlé Research, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH